Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence

Yogesh Punekar(ViiV Healthcare (United Kingdom)), Annemiek de Ruiter(ViiV Healthcare (Spain)), Sophia Sharma(PAREXEL International (India)), Vasiliki Chounta(Triangle), Mihir Joshi(GlaxoSmithKline (United Kingdom)), Daniel Parks(GlaxoSmithKline (United States)), M. Radford(ViiV Healthcare (United Kingdom)), Lee Evitt(ViiV Healthcare (United Kingdom)), SIMARJIT KAUR(PAREXEL International (India)), Jean van Wyk(ViiV Healthcare (United Kingdom)), D. Jha(GlaxoSmithKline (United Kingdom)), Shannon Ferrante(GlaxoSmithKline (United States))
HIV Medicine
February 2, 2021
10.1111/hiv.13050
Cited by 45

Related Papers

Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006
|AIDS|2008|582
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population
|Infectious Diseases and Therapy|2018|197